{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:43:24Z","timestamp":1791380604589,"version":"4.3.3"},"reference-count":11,"publisher":"MedWorks Media","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"\n Background<\/jats:title>\n Suzetrigine is a novel non-opioid analgesic initially approved for acute pain management. There has been growing interest in its potential applications for chronic pain conditions. As clinical awareness and accessibility expand, evaluating early outpatient prescribing patterns is essential to better understand its adoption and possible role in broader pain management strategies.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate outpatient prescribing trends of suzetrigine at a single academic institution over 5 months to evaluate early adoption and prescription trends.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This retrospective observational study examined outpatient prescriptions of suzetrigine from March 1, 2025, to July 31, 2025. Prescription counts were extracted from the institutional electronic medical record system and analyzed by month.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 367 Suzetrigine prescriptions were written over the 5-month period. Monthly distribution was as follows:<\/jats:p>\n There was a clear upward trend in prescribing from March to July. This increase may reflect growing provider familiarity and favorable patient response to the medication.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Suzetrigine outpatient prescribing has increased significantly over a short time frame at our institution. Continued monitoring of prescription trends, indications, and patient outcomes will be essential as this medication becomes more widely utilized in pain management.<\/jats:p>\n <\/jats:sec>","DOI":"10.64719\/pb.16578","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:16:27Z","timestamp":1773260187000},"page":"52-57","source":"Crossref","is-referenced-by-count":2,"title":["Suzetrigine for Pain Management: An Observational Study of Early Adoption Patterns"],"prefix":"10.64719","volume":"56","author":[{"given":"Jamal","family":"Hasoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Urits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farnad","family":"Imani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Abd-Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Gorfinkel LR, Hasin D, Saxon AJ et al. Trends in prescriptions for non-opioid pain medications among U.S. adults with moderate or severe pain, 2014\u20132018. J Pain. 2022;23(7):1187\u20131195. doi: 10.1016\/j.jpain.2022.01.006. Epub 2022 Feb 8.","DOI":"10.1016\/j.jpain.2022.01.006"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Cerda IH, Jung H, Guerrero MC et al. Trends in celecoxib prescribing: a single institution 16-month review. J Clin Med. 2025;14(8):2823. doi: 10.3390\/jcm14082823.","DOI":"10.3390\/jcm14082823"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Keshwani S, Smith SM, Brown J et al. Trends in prescribing of non-steroidal anti-inflammatory medications in the US ambulatory care setting from 2006 to 2016. J Pain. 2023;24(11):1994\u20132002. doi: 10.1016\/j.jpain.2023.06.008. Epub 2023 Jun 15.","DOI":"10.1016\/j.jpain.2023.06.008"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Tran RT, Patil AS, Nguyen PP et al. Prescribing patterns of gabapentinoids in chronic pain management: a single institution retrospective chart review. Psychopharmacol Bull. 2025;55(1):26\u201336.","DOI":"10.64719\/pb.4510"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Goudman L, Moens M, Pilitsis JG. Incidence and prevalence of pain medication prescriptions in pathologies with a potential for chronic pain. Anesthesiology. 2024;140(3):524\u2013537. doi: 10.1097\/ALN.0000000000004863.","DOI":"10.1097\/ALN.0000000000004863"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Bertoch T, D\u2019Aunno D, McCoun J et al. Suzetrigine, a Nonopioid Na V 1.8 inhibitor for treatment of moderate-to-severe acute pain: two phase 3 randomized clinical trials. Anesthesiology. 2025;142(6):1085\u20131099. doi: 10.1097\/ALN.0000000000005460. Epub 2025 Mar 21.","DOI":"10.1097\/ALN.0000000000005460"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Keam SJ. Suzetrigine: first approval. Drugs. 2025;85(6):845\u2013851. doi: 10.1007\/s40265-025-02178-w. Epub 2025 May 5.","DOI":"10.1007\/s40265-025-02178-w"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Bhattacharya K, Bazzazzadehgan S, Leong NWI et al. Prescription opioid use in older adults: trends and changes in new and long-term use in the United States, 2013\u20132020. Drugs Aging. 2025 doi: 10.1007\/s40266-025-01237-x. Epub ahead of print.","DOI":"10.1007\/s40266-025-01237-x"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain \u2013 United States, 2022. MMWR Recomm Rep. 2022;71(3):1\u201395. doi: 10.15585\/mmwr.rr7103a1.","DOI":"10.15585\/mmwr.rr7103a1"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Hasoon J, Qadeer A, Chen GH, Viswanath O, Urits I, Robinson CL. Methadone prescribing patterns at a single institution: a retrospective study and clinical implications. Psychopharmacol Bull. 2025;55(4):43\u201354.","DOI":"10.64719\/pb.4548"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Hasoon J, Chitneni A, Viswanath O, Urits I, Imani F, Varrassi G. Trends in outpatient buprenorphine prescribing for chronic pain: a retrospective analysis over 18 months. Psychopharmacol Bull. 2025;55(3):8\u201319.","DOI":"10.64719\/pb.4529"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:36:32Z","timestamp":1791315392000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/suzetrigine-for-pain-management-an-observational-study-of-early-adoption-patterns\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":11,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3,9]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.16578","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]}}}